DJIA 18,053.71 23.50 0.13%
NASDAQ 4,806.86 33.39 0.70%
S&P 500 2,088.77 6.89 0.33%
market minute promo

VIVUS, Inc. (NASDAQ: VVUS)



company name or ticker

Is Vivus Headed Towards An Unfortunate Ending?

The Newest FDA-Approved Obesity Drug Is Also the Oldest

Novo Nordisk gains FDA approval for Saxenda, which is already approved as an obesity treatment called Victoza.

3 Stocks Poised for Eye-Popping Gains in 2015

Gilead Sciences, Orexigen Therapeutics, and Prothena Corp. are all poised to have a huge 2015. Here's what investors need to know.

3 Biotech Stocks I Don't Want for Christmas

I’d prefer coal in my stocking to these three troubled biotech stocks.

Novo Nordisk Enters Anti-Obesity Space With New FDA Approval

Contrave Prescriptions Still Rising In A Down Week

Orexigen - Contrave Script Numbers Remain Impressive

Buying These 3 Stocks Is Like Making a Bet in a Burning House

Aegerion Pharmaceuticals, MannKind Corp., and VIVUS, Inc. have all attracted short sellers in droves this year. With each company facing serious headwinds, should investors avoid these struggling biotechs?

New Obesity Drug Available Soon

Orexigen is close to getting Mysimba on the market in Europe.

Arena And Vivus Investors Need To Grasp Implications Of Orexigen

See More Articles...